Skip to main content

HCPCS Level II

HCPCS Level II 2015 code changes

Every HCPCS Level II code whose CMS add date or termination date falls in 2015, grouped by effective date. Each code's own page carries its full record.

234
Added
162
Deleted

For HCPCS Level II, MedCoder records each code's CMS add date and termination date from the alpha-numeric file. A deletion is listed on the first day the code is no longer valid (the day after its CMS termination date). Description revisions between quarterly files are not recorded as changes.

Added effective January 1, 2015 (208)

  • A4459 — Manual transanal irrigation system, includes water reservoir, pump, tubing, and accessories, without catheter, any type
  • A4602 — Replacement battery for external infusion pump owned by patient, lithium, 1.5 volt, each
  • A7048 — Vacuum drainage collection unit and tubing kit, including all supplies needed for collection unit change, for use with implanted catheter, each
  • A9606 — Radium ra-223 dichloride, therapeutic, per microcurie
  • C2624 — Implantable wireless pulmonary artery pressure sensor with delivery catheter, including all system components
  • C9027 — Injection, pembrolizumab, 1 mg
  • C9136 — Injection, factor viii, fc fusion protein, (recombinant), per i.u.
  • C9349 — Puraply, and puraply antimicrobial, any type, per square centimeter
  • C9442 — Injection, belinostat, 10 mg
  • C9443 — Injection, dalbavancin, 10 mg
  • C9444 — Injection, oritavancin, 10 mg
  • C9446 — Injection, tedizolid phosphate, 1 mg
  • C9447 — Injection, phenylephrine and ketorolac, 4 ml vial
  • C9742 — Laryngoscopy, flexible fiberoptic, with injection into vocal cord(s), therapeutic, including diagnostic laryngoscopy, if performed
  • G0276 — Blinded procedure for lumbar stenosis, percutaneous image-guided lumbar decompression (pild) or placebo-control, performed in an approved coverage with evidence development (ced) clinical trial
  • G0277 — Hyperbaric oxygen under pressure, full body chamber, per 30 minute interval
  • G0279 — Diagnostic digital breast tomosynthesis, unilateral or bilateral (list separately in addition to 77065 or 77066)
  • G0473 — Face-to-face behavioral counseling for obesity, group (2-10), 30 minutes
  • G6001 — Ultrasonic guidance for placement of radiation therapy fields
  • G6002 — Stereoscopic x-ray guidance for localization of target volume for the delivery of radiation therapy
  • G6003 — Radiation treatment delivery, single treatment area, single port or parallel opposed ports, simple blocks or no blocks: up to 5 mev
  • G6004 — Radiation treatment delivery, single treatment area, single port or parallel opposed ports, simple blocks or no blocks: 6-10 mev
  • G6005 — Radiation treatment delivery, single treatment area, single port or parallel opposed ports, simple blocks or no blocks: 11-19 mev
  • G6006 — Radiation treatment delivery, single treatment area, single port or parallel opposed ports, simple blocks or no blocks: 20 mev or greater
  • G6007 — Radiation treatment delivery, 2 separate treatment areas, 3 or more ports on a single treatment area, use of multiple blocks: up to 5 mev
  • G6008 — Radiation treatment delivery, 2 separate treatment areas, 3 or more ports on a single treatment area, use of multiple blocks: 6-10 mev
  • G6009 — Radiation treatment delivery, 2 separate treatment areas, 3 or more ports on a single treatment area, use of multiple blocks: 11-19 mev
  • G6010 — Radiation treatment delivery, 2 separate treatment areas, 3 or more ports on a single treatment area, use of multiple blocks: 20 mev or greater
  • G6011 — Radiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; up to 5 mev
  • G6012 — Radiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 6-10 mev
  • G6013 — Radiation treatment delivery,3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 11-19 mev
  • G6014 — Radiation treatment delivery, 3 or more separate treatment areas, custom blocking, tangential ports, wedges, rotational beam, compensators, electron beam; 20 mev or greater
  • G6015 — Intensity modulated treatment delivery, single or multiple fields/arcs,via narrow spatially and temporally modulated beams, binary, dynamic mlc, per treatment session
  • G6016 — Compensator-based beam modulation treatment delivery of inverse planned treatment using 3 or more high resolution (milled or cast) compensator, convergent beam modulated fields, per treatment session
  • G6017 — Intra-fraction localization and tracking of target or patient motion during delivery of radiation therapy (eg,3d positional tracking, gating, 3d surface tracking), each fraction of treatment
  • G6018 — Ileoscopy, through stoma; with transendoscopic stent placement (includes predilation)
  • G6019 — Colonoscopy through stoma; with ablation of tumor(s), polyp(s), or other lesion(s) not amenable to removal by hot biopsy forceps, bipolar cautery or snare technique
  • G6020 — Colonoscopy through stoma; with transendoscopic stent placement (includes predilation)
  • G6021 — Unlisted procedure, intestine
  • G6022 — Sigmoidoscopy, flexible; with ablation of tumor(s), polyp(s), or other lesions(s) not amenable to removal by hot biopsy forceps, bipolar cautery or snare technique
  • G6023 — Sigmoidoscopy, flexible; with transendoscopic stent placement (includes predilation)
  • G6024 — Colonoscopy, flexible; proximal to splenic flexure; with ablation of tumor(s), polyp(s), or other lesion(s) not amenable to removal by hot biopsy forceps, bipolar cautery or snare technique
  • G6025 — Colonoscopy, flexible, proximal to splenic flexure; with transendoscopic stent placement (includes predilation)
  • G6027 — Anoscopy, high resolution (hra) (with magnification and chemical agent enhancement); diagnostic, including collection of specimen(s) by brushing or washing when performed
  • G6028 — Anoscopy, high resolution (hra) (with magnification and chemical agent enhancement); with biopsy(ies)
  • G6030 — Amitriptyline
  • G6031 — Benzodiazepines
  • G6032 — Desipramine
  • G6034 — Doxepin
  • G6035 — Gold
  • G6036 — Assay of imipramine
  • G6037 — Nortriptyline
  • G6038 — Salicylate
  • G6039 — Acetaminophen
  • G6040 — Alcohol (ethanol); any specimen except breath
  • G6041 — Alkaloids, urine, quantitative
  • G6042 — Amphetamine or methamphetamine
  • G6043 — Barbiturates, not elsewhere specified
  • G6044 — Cocaine or metabolite
  • G6045 — Dihydrocodeinone
  • G6046 — Dihydromorphinone
  • G6047 — Dihydrotestosterone
  • G6048 — Dimethadione
  • G6049 — Epiandrosterone
  • G6050 — Ethchlorvynol
  • G6051 — Flurazepam
  • G6052 — Meprobamate
  • G6053 — Methadone
  • G6054 — Methsuximide
  • G6055 — Nicotine
  • G6056 — Opiate(s), drug and metabolites, each procedure
  • G6057 — Phenothiazine
  • G6058 — Drug confirmation, each procedure
  • G9362 — Duration of monitored anesthesia care (mac) or peripheral nerve block (pnb) without the use of general anesthesia during an applicable procedure 60 minutes or longer, as documented in the anesthesia record
  • G9363 — Duration of monitored anesthesia care (mac) or peripheral nerve block (pnb) without the use of general anesthesia during an applicable procedure or general or neuraxial anesthesia less than 60 minutes, as documented in the anesthesia record
  • G9364 — Sinusitis caused by, or presumed to be caused by, bacterial infection
  • G9365 — One high-risk medication ordered
  • G9366 — One high-risk medication not ordered
  • G9367 — At least two orders for high-risk medications from the same drug class
  • G9368 — At least two orders for high-risk medications from the same drug class not ordered
  • G9369 — Individual filled at least two prescriptions for any antipsychotic medication and had a pdc of 0.8 or greater
  • G9370 — Individual who did not fill at least two prescriptions for any antipsychotic medication or did not have a pdc of 0.8 or greater
  • G9376 — Patient continued to have the retina attached at the 6 months follow up visit (+/- 1 month) following only one surgery
  • G9377 — Patient did not have the retina attached after 6 months following only one surgery
  • G9378 — Patient continued to have the retina attached at the 6 months follow up visit (+/- 1 month)
  • G9379 — Patient did not achieve flat retinas six months post surgery
  • G9380 — Patient offered assistance with end of life issues or existing end of life plan was reviewed or updated during the measurement period
  • G9381 — Documentation of medical reason(s) for not offering assistance with end of life issues (e.g., patient in hospice care, patient in terminal phase) during the measurement period
  • G9382 — Patient not offered assistance with end of life issues or existing end of life plan was not reviewed or updated during the measurement period
  • G9383 — Patient received screening for hcv infection within the 12 month reporting period
  • G9384 — Documentation of medical reason(s) for not receiving annual screening for hcv infection (e.g., decompensated cirrhosis indicating advanced disease [i.e., ascites, esophageal variceal bleeding, hepatic encephalopathy], hepatocellular carcinoma, waitlist for organ transplant, limited life expectancy, other medical reasons)
  • G9385 — Documentation of patient reason(s) for not receiving annual screening for hcv infection (e.g., patient declined, other patient reasons)
  • G9386 — Screening for hcv infection not received within the 12 month reporting period, reason not given
  • G9389 — Unplanned rupture of the posterior capsule requiring vitrectomy during cataract surgery
  • G9390 — No unplanned rupture of the posterior capsule requiring vitrectomy during cataract surgery
  • G9391 — Patient achieves refraction +-1 d for the eye that underwent cataract surgery, measured at the one month follow up visit
  • G9392 — Patient does not achieve refraction +-1 d for the eye that underwent cataract surgery, measured at the one month follow up visit
  • G9393 — Patient with an initial phq-9 score greater than nine who achieves remission at twelve months as demonstrated by a twelve month (+/- 30 days) phq-9 score of less than five
  • G9394 — Patient who had a diagnosis of bipolar disorder or personality disorder, death, permanent nursing home resident or receiving hospice or palliative care any time during the measurement or assessment period
  • G9395 — Patient with an initial phq-9 score greater than nine who did not achieve remission at twelve months as demonstrated by a twelve month (+/- 30 days) phq-9 score greater than or equal to five
  • G9396 — Patient with an initial phq-9 score greater than nine who was not assessed for remission at twelve months (+/- 30 days)
  • G9399 — Documentation in the patient record of a discussion between the physician/clinician and the patient that includes all of the following: treatment choices appropriate to genotype, risks and benefits, evidence of effectiveness, and patient preferences toward the outcome of the treatment
  • G9400 — Documentation of medical or patient reason(s) for not discussing treatment options; medical reasons: patient is not a candidate for treatment due to advanced physical or mental health comorbidity (including active substance use); currently receiving antiviral treatment; successful antiviral treatment (with sustained virologic response) prior to reporting period; other documented medical reasons; patient reasons: patient unable or unwilling to participate in the discussion or other patient reasons
  • G9401 — No documentation in the patient record of a discussion between the physician or other qualified healthcare professional and the patient that includes all of the following: treatment choices appropriate to genotype, risks and benefits, evidence of effectiveness, and patient preferences toward treatment
  • G9402 — Patient received follow-up within 30 days after discharge
  • G9403 — Clinician documented reason patient was not able to complete 30 day follow-up from acute inpatient setting discharge (e.g., patient death prior to follow-up visit, patient non-compliant for visit follow-up)
  • G9404 — Patient did not receive follow-up within 30 days after discharge
  • G9405 — Patient received follow-up within 7 days after discharge
  • G9406 — Clinician documented reason patient was not able to complete 7 day follow-up from acute inpatient setting discharge (i.e patient death prior to follow-up visit, patient non-compliance for visit follow-up)
  • G9407 — Patient did not receive follow-up within 7 days after discharge
  • G9408 — Patients with cardiac tamponade and/or pericardiocentesis occurring within 30 days
  • G9409 — Patients without cardiac tamponade and/or pericardiocentesis occurring within 30 days
  • G9410 — Patient admitted within 180 days, status post cied implantation, replacement, or revision with an infection requiring device removal or surgical revision
  • G9411 — Patient not admitted within 180 days, status post cied implantation, replacement, or revision with an infection requiring device removal or surgical revision
  • G9412 — Patient admitted within 180 days, status post cied implantation, replacement, or revision with an infection requiring device removal or surgical revision
  • G9413 — Patient not admitted within 180 days, status post cied implantation, replacement, or revision with an infection requiring device removal or surgical revision
  • G9414 — Patient had one dose of meningococcal vaccine (serogroups a, c, w, y or a, c, w, y, b) on or between the patient's 10th and 13th birthdays
  • G9415 — Patient did not have one dose of meningococcal vaccine (serogroups a, c, w, y or a, c, w, y, b), on or between the patient's 10th and 13th birthdays
  • G9416 — Patient had one tetanus, diphtheria toxoids and acellular pertussis vaccine (tdap) on or between the patient's 10th and 13th birthdays
  • G9417 — Patient did not have one tetanus, diphtheria toxoids and acellular pertussis vaccine (tdap) on or between the patient's 10th and 13th birthdays
  • G9418 — Primary non-small cell lung cancer lung biopsy and cytology specimen report documents classification into specific histologic type following iaslc guidance or classified as nsclc-nos with an explanation
  • G9419 — Documentation of medical reason(s) for not including the histological type or nsclc-nos classification with an explanation (e.g. specimen insufficient or non-diagnostic, specimen does not contain cancer, or other documented medical reasons)
  • G9420 — Specimen site other than anatomic location of lung or is not classified as primary non-small cell lung cancer
  • G9421 — Primary non-small cell lung cancer lung biopsy and cytology specimen report does not document classification into specific histologic type or histologic type does not follow iaslc guidance or is classified as nsclc-nos but without an explanation
  • G9422 — Primary lung carcinoma resection report documents pt category, pn category and for non-small cell lung cancer, histologic type (e.g., squamous cell carcinoma, adenocarcinoma and not nsclc-nos)
  • G9423 — Documentation of medical reason for not including pt category, pn category and histologic type [for patient with appropriate exclusion criteria (e.g., metastatic disease, benign tumors, malignant tumors other than carcinomas, inadequate surgical specimens)]
  • G9424 — Specimen site other than anatomic location of lung, or classified as nsclc-nos
  • G9425 — Primary lung carcinoma resection report does not document pt category, pn category and for non-small cell lung cancer, histologic type (e.g., squamous cell carcinoma, adenocarcinoma)
  • G9426 — Improvement in median time from ed arrival to initial ed oral or parenteral pain medication administration performed for ed admitted patients
  • G9427 — Improvement in median time from ed arrival to initial ed oral or parenteral pain medication administration not performed for ed admitted patients
  • G9428 — Pathology report includes the pt category, thickness, ulceration and mitotic rate, peripheral and deep margin status and presence or absence of microsatellitosis for invasive tumors
  • G9429 — Documentation of medical reason(s) for not including pt category, thickness, ulceration and mitotic rate, peripheral and deep margin status and presence or absence of microsatellitosis for invasive tumors (e.g., negative skin biopsies, insufficient tissue, or other documented medical reasons)
  • G9430 — Specimen site other than anatomic cutaneous location
  • G9431 — Pathology report does not include the pt category, thickness, ulceration and mitotic rate, peripheral and deep margin status and presence or absence of microsatellitosis for invasive tumors
  • G9432 — Asthma well-controlled based on the act, c-act, acq, or ataq score and results documented
  • G9433 — Death, permanent nursing home resident or receiving hospice or palliative care any time during the measurement period
  • G9434 — Asthma not well-controlled based on the act, c-act, acq, or ataq score, or specified asthma control tool not used, reason not given
  • G9435 — Aspirin prescribed at discharge
  • G9436 — Aspirin not prescribed for documented reasons (e.g., allergy, medical intolerance, history of bleed)
  • G9437 — Aspirin not prescribed at discharge
  • G9438 — P2y inhibitor prescribed at discharge
  • G9439 — P2y inhibitor not prescribed for documented reasons (e.g., allergy, medical intolerance, history of bleed)
  • G9440 — P2y inhibitor not prescribed at discharge
  • G9441 — Statin prescribed at discharge
  • G9442 — Statin not prescribed for documented reasons (e.g., allergy, medical intolerance)
  • G9443 — Statin not prescribed at discharge
  • G9448 — Patients who were born in the years 1945 to 1965
  • G9449 — History of receiving blood transfusions prior to 1992
  • G9450 — History of injection drug use
  • G9451 — Patient received one-time screening for hcv infection
  • G9452 — Documentation of medical reason(s) for not receiving hcv antibody test due to limited life expectancy
  • G9453 — Documentation of patient reason(s) for not receiving one-time screening for hcv infection (e.g., patient declined, other patient reasons)
  • G9454 — One-time screening for hcv infection not received within 12-month reporting period and no documentation of prior screening for hcv infection, reason not given
  • G9455 — Patient underwent abdominal imaging with ultrasound, contrast enhanced ct or contrast mri for hcc
  • G9456 — Documentation of medical or patient reason(s) for not ordering or performing screening for hcc. medical reason: comorbid medical conditions with expected survival < 5 years, hepatic decompensation and not a candidate for liver transplantation, or other medical reasons; patient reasons: patient declined or other patient reasons (e.g., cost of tests, time related to accessing testing equipment)
  • G9457 — Patient did not undergo abdominal imaging and did not have a documented reason for not undergoing abdominal imaging in the submission period
  • G9458 — Patient documented as tobacco user and received tobacco cessation intervention (must include at least one of the following: advice given to quit smoking or tobacco use, counseling on the benefits of quitting smoking or tobacco use, assistance with or referral to external smoking or tobacco cessation support programs, or current enrollment in smoking or tobacco use cessation program) if identified as a tobacco user
  • G9459 — Currently a tobacco non-user
  • G9460 — Tobacco assessment or tobacco cessation intervention not performed, reason not given
  • G9463 — I intend to report the sinusitis measures group
  • G9464 — All quality actions for the applicable measures in the sinusitis measures group have been performed for this patient
  • G9465 — I intend to report the acute otitis externa (aoe) measures group
  • G9466 — All quality actions for the applicable measures in the aoe measures group have been performed for this patient
  • G9467 — Patient who have received or are receiving corticosteroids greater than or equal to 10 mg/day of prednisone equivalents for 60 or greater consecutive days or a single prescription equating to 600 mg prednisone or greater for all fills within the last twelve months
  • G9468 — Patient not receiving corticosteroids greater than or equal to 10 mg/day of prednisone equivalents for 60 or greater consecutive days or a single prescription equating to 600 mg prednisone or greater for all fills
  • G9469 — Patients who have received or are receiving corticosteroids greater than or equal to 10 mg/day of prednisone equivalents for 90 or greater consecutive days or a single prescription equating to 900 mg prednisone or greater for all fills
  • G9470 — Patients not receiving corticosteroids greater than or equal to 10 mg/day of prednisone equivalents for 60 or greater consecutive days or a single prescription equating to 600 mg prednisone or greater for all fills
  • G9471 — Within the past 2 years, central dual-energy x-ray absorptiometry (dxa) not ordered or documented
  • G9472 — Within the past 2 years, central dual-energy x-ray absorptiometry (dxa) not ordered and documented, no review of systems and no medication history or pharmacologic therapy (other than minerals/vitamins) for osteoporosis prescribed
  • J0153 — Injection, adenosine, 1 mg (not to be used to report any adenosine phosphate compounds)
  • J0571 — Buprenorphine, oral, 1 mg
  • J0572 — Buprenorphine/naloxone, oral, less than or equal to 3 mg buprenorphine
  • J0573 — Buprenorphine/naloxone, oral, greater than 3 mg, but less than or equal to 6 mg buprenorphine
  • J0574 — Buprenorphine/naloxone, oral, greater than 6 mg, but less than or equal to 10 mg buprenorphine
  • J0575 — Buprenorphine/naloxone, oral, greater than 10 mg buprenorphine
  • J0887 — Injection, epoetin beta, 1 microgram, (for esrd on dialysis)
  • J0888 — Injection, epoetin beta, 1 microgram, (for non esrd use)
  • J1071 — Injection, testosterone cypionate, 1 mg
  • J1322 — Injection, elosulfase alfa, 1 mg
  • J1439 — Injection, ferric carboxymaltose, 1 mg
  • J2274 — Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg
  • J2704 — Injection, propofol, 10 mg
  • J3121 — Injection, testosterone enanthate, 1 mg
  • J3145 — Injection, testosterone undecanoate, 1 mg
  • J7181 — Injection, factor xiii a-subunit, (recombinant), per iu
  • J7182 — Injection, factor viii, (antihemophilic factor, recombinant), (novoeight), per iu
  • J7200 — Injection, factor ix, (antihemophilic factor, recombinant), rixubis, per iu
  • J7201 — Injection, factor ix, fc fusion protein, (recombinant), alprolix, 1 i.u.
  • J7327 — Hyaluronan or derivative, monovisc, for intra-articular injection, per dose
  • J7336 — Capsaicin 8% patch, per square centimeter
  • J9267 — Injection, paclitaxel, 1 mg
  • J9301 — Injection, obinutuzumab, 10 mg
  • L3981 — Upper extremity fracture orthosis, humeral, prefabricated, includes shoulder cap design, with or without joints, forearm section, may include soft interface, straps, includes fitting and adjustments
  • L6026 — Transcarpal/metacarpal or partial hand disarticulation prosthesis, external power, self-suspended, inner socket with removable forearm section, electrodes and cables, two batteries, charger, myoelectric control of terminal device, excludes terminal device(s)
  • L7259 — Electronic wrist rotator, any type
  • L8696 — Antenna (external) for use with implantable diaphragmatic/phrenic nerve stimulation device, replacement, each
  • Q4150 — Allowrap ds or dry, per square centimeter (add-on, list separately in addition to primary procedure)
  • Q4151 — Amnioband or guardian, per square centimeter (add-on, list separately in addition to primary procedure)
  • Q4152 — Dermapure, per square centimeter (add-on, list separately in addition to primary procedure)
  • Q4153 — Dermavest and plurivest, per square centimeter (add-on, list separately in addition to primary procedure)
  • Q4154 — Biovance, per square centimeter (add-on, list separately in addition to primary procedure)
  • Q4155 — Neoxflo or clarixflo, 1 mg
  • Q4156 — Neox 100 or clarix 100, per square centimeter (add-on, list separately in addition to primary procedure)
  • Q4157 — Revitalon, per square centimeter (add-on, list separately in addition to primary procedure)
  • Q4158 — Kerecis omega3, per square centimeter (add-on, list separately in addition to primary procedure)
  • Q4159 — Affinity, per square centimeter (add-on, list separately in addition to primary procedure)
  • Q4160 — Nushield, per square centimeter (add-on, list separately in addition to primary procedure)
  • S9901 — Services by a journal-listed christian science nurse, per hour

Deleted effective January 1, 2015 (158)

  • A7042 — Implanted pleural catheter, each
  • A7043 — Vacuum drainage bottle and tubing for use with implanted catheter
  • C1300 — Hyperbaric oxygen under pressure, full body chamber, per 30 minute interval
  • C9021 — Injection, obinutuzumab, 10 mg
  • C9022 — Injection, elosulfase alfa, 1mg
  • C9023 — Injection, testosterone undecanoate, 1 mg
  • C9133 — Factor ix (antihemophilic factor, recombinant), rixubis, per i.u.
  • C9134 — Factor xiii (antihemophilic factor, recombinant), tretten, per 10 i.u.
  • C9135 — Factor ix (antihemophilic factor, recombinant), alprolix, per i.u.
  • C9735 — Anoscopy; with directed submucosal injection(s), any substance
  • G0173 — Linear accelerator based stereotactic radiosurgery, complete course of therapy in one session
  • G0251 — Linear accelerator based stereotactic radiosurgery, delivery including collimator changes and custom plugging, fractionated treatment, all lesions, per session, maximum five sessions per course of treatment
  • G0417 — Surgical pathology, gross and microscopic examination, for prostate needle biopsy, any method, 21-40 specimens
  • G0418 — Surgical pathology, gross and microscopic examination, for prostate needle biopsy, any method, 41-60 specimens
  • G0419 — Surgical pathology, gross and microscopic examination, for prostate needle biopsy, any method, >60 specimens
  • G0456 — Negative pressure wound therapy, (e.g. vacuum assisted drainage collection) using a mechanically-powered device, not durable medical equipment, including provision of cartridge and dressing(s), topical application(s), wound assessment, and instructions for ongoing care, per session; total wounds(s) surface area less than or equal to 50 square centimeters
  • G0457 — Negative pressure wound therapy, (e.g. vacuum assisted drainage collection) using a mechanically-powered device, not durable medical equipment, including provision of cartridge and dressing(s), topical application(s), wound assessment, and instructions for ongoing care, per session; total wounds(s) surface area greater than 50 square centimeters
  • G0461 — Immunohistochemistry or immunocytochemistry, per specimen; first single or multiplex antibody stain
  • G0462 — Immunohistochemistry or immunocytochemistry, per specimen; each additional single or multiplex antibody stain (list separately in addition to code for primary procedure)
  • G0908 — Most recent hemoglobin (hgb) level > 12.0 g/dl
  • G0909 — Hemoglobin level measurement not documented, reason not given
  • G0910 — Most recent hemoglobin level <= 12.0 g/dl
  • G0919 — Influenza immunization ordered or recommended (to be given at alternate location or alternate provider); vaccine not available at time of visit
  • G0920 — Type, anatomic location, and activity all documented
  • G0921 — Documentation of patient reason(s) for not being able to assess (e.g., patient refuses endoscopic and/or radiologic assessment)
  • G0922 — No documentation of disease type, anatomic location, and activity, reason not given
  • G8126 — Patient with a diagnosis of major depression documented as being treated with antidepressant medication during the entire 84 day (12 week) acute treatment phase
  • G8127 — Patient with a diagnosis of major depression not documented as being treated with antidepressant medication during the entire 84 day (12 week) acute treatment phase
  • G8128 — Clinician documented that patient was not an eligible candidate for antidepressant medication during the entire 12 week acute treatment phase measure
  • G8406 — Clinician documented that patient was not an eligible candidate for lower extremity neurological exam measure
  • G8464 — Clinician documented that prostate cancer patient is not an eligible candidate for adjuvant hormonal therapy; low or intermediate risk of recurrence or risk of recurrence not determined
  • G8492 — I intend to report the perioperative care measures group
  • G8493 — I intend to report the back pain measures group
  • G8501 — All quality actions for the applicable measures in the perioperative care measures group have been performed for this patient
  • G8502 — All quality actions for the applicable measures in the back pain measures group have been performed for this patient
  • G8547 — I intend to report the ischemic vascular disease (ivd) measures group
  • G8552 — All quality actions for the applicable measures in the ischemic vascular disease (ivd) measures group have been performed for this patient
  • G8579 — Antiplatelet medication at discharge
  • G8580 — Antiplatelet medication contraindicated
  • G8581 — No antiplatelet medication at discharge
  • G8582 — Beta-blocker at discharge
  • G8583 — Beta-blocker contraindicated
  • G8584 — No beta-blocker at discharge
  • G8585 — Anti-lipid treatment at discharge
  • G8586 — Anti-lipid treatment contraindicated
  • G8587 — No anti-lipid treatment at discharge
  • G8593 — Lipid profile results documented and reviewed (must include total cholesterol, hdl-c, triglycerides and calculated ldl-c)
  • G8594 — Lipid profile not performed, reason not given
  • G8595 — Most recent ldl-c < 100 mg/dl
  • G8597 — Most recent ldl-c >= 100 mg/dl
  • G8629 — Documentation of order for prophylactic parenteral antibiotic to be given within one hour (if fluoroquinolone or vancomycin, two hours) prior to surgical incision (or start of procedure when no incision is required)
  • G8630 — Documentation that administration of prophylactic parenteral antibiotics was initiated within one hour (if fluoroquinolone or vancomycin, two hours) prior to surgical incision (or start of procedure when no incision is required), as ordered
  • G8631 — Clinician documented that patient was not an eligible candidate for ordering prophylactic parenteral antibiotics to be given within one hour (if fluoroquinolone or vancomycin, two hours) prior to surgical incision (or start of procedure when no incision is required)
  • G8632 — Prophylactic parenteral antibiotics were not ordered to be given or given within one hour (if fluoroquinolone or vancomycin, two hours) prior to the surgical incision (or start of procedure when no incision is required), reason not given
  • G8682 — Lvf testing documented as being performed prior to discharge or in the previous 12 months
  • G8683 — Lvf testing not performed prior to discharge or in the previous 12 months for a medical or patient documented reason
  • G8685 — Lvf testing not documented as being performed prior to discharge or in the previous 12 months, reason not given
  • G8699 — Rehabilitation services (occupational, physical or speech) ordered at or prior to discharge
  • G8700 — Rehabilitation services (occupational, physical or speech) not indicated at or prior to discharge
  • G8701 — Rehabilitation services were not ordered, reason not otherwise specified
  • G8702 — Documentation that prophylactic antibiotics were given within 4 hours prior to surgical incision or intraoperatively
  • G8703 — Documentation that prophylactic antibiotics were neither given within 4 hours prior to surgical incision nor intraoperatively
  • G8704 — 12-lead electrocardiogram (ecg) performed
  • G8705 — Documentation of medical reason(s) for not performing a 12-lead electrocardiogram (ecg)
  • G8706 — Documentation of patient reason(s) for not performing a 12-lead electrocardiogram (ecg)
  • G8707 — 12-lead electrocardiogram (ecg) not performed, reason not given
  • G8736 — Most current ldl-c <100mg/dl
  • G8737 — Most current ldl-c >=100mg/dl
  • G8738 — Left ventricular ejection fraction (lvef) < 40% or documentation of severely or moderately depressed left ventricular systolic function
  • G8739 — Left ventricular ejection fraction (lvef) >= 40% or documentation as normal or mildly depressed left ventricular systolic function
  • G8740 — Left ventricular ejection fraction (lvef) not performed or assessed, reason not given
  • G8751 — Smoking status and exposure to second hand smoke in the home not assessed, reason not given
  • G8763 — All quality actions for the applicable measures in the hypertension (htn) measures group have been performed for this patient
  • G8764 — All quality actions for the applicable measures in the cardiovascular prevention measures group have bee performed for this patient
  • G8767 — Lipid panel results documented and reviewed (must include total cholesterol, hdl-c, triglycerides and calculated ldl-c)
  • G8768 — Documentation of medical reason(s) for not performing lipid profile (e.g., patients with palliative goals or for whom treatment of hypertension with standard treatment goals is not clinically appropriate)
  • G8769 — Lipid profile not performed, reason not given
  • G8770 — Urine protein test result documented and reviewed
  • G8771 — Documentation of diagnosis of chronic kidney disease
  • G8772 — Documentation of medical reason(s) for not performing urine protein test (e.g., patients with palliative goals or for whom treatment of hypertension with standard treatment goals is not cllinically appropriate)
  • G8773 — Urine protein test was not performed, reason not given
  • G8774 — Serum creatinine test result documented and reviewed
  • G8775 — Documentation of medical reason(s) for not performing serum creatinine test (e.g., patients with palliative goals or for whom treatment of hypertension with standard treatment goals is not clinically appropriate)
  • G8776 — Serum creatinine test not performed, reason not given
  • G8777 — Diabetes screening test performed
  • G8778 — Documentation of medical reason(s) for not performing diabetes screening test (e.g., patients with a diagnosis of diabetes, or with palliative goals or for whom treatment of hypertension with standard treatment goals is not clinically appropriate)
  • G8779 — Diabetes screening test not performed, reason not given
  • G8780 — Counseling for diet and physical activity performed
  • G8781 — Documentation of medical reason(s) for patient not receiving counseling for diet and physical activity (e.g., patients with palliative goals or for whom treatment of hypertension with standard treatment goals is not clinically appropriate)
  • G8782 — Counseling for diet and physical activity not performed, reason not given
  • G8859 — Patient receiving corticosteroids greater than or equal to 10mg/day for 60 or greater consecutive days
  • G8860 — Patients who have received dose of corticosteroids greater than or equal to 10mg/day for 60 or greater consecutive days
  • G8862 — Patients not receiving corticosteroids greater than or equal to 10mg/day for 60 or greater consecutive days
  • G8886 — Most recent blood pressure under control
  • G8887 — Documentation of medical reason(s) for most recent blood pressure not being under control (e.g., patients with palliative goals or for whom treatment of hypertension with standard treatment goals is not clinically appropriate)
  • G8888 — Most recent blood pressure not under control, results documented and reviewed
  • G8889 — No documentation of blood pressure measurement, reason not given
  • G8890 — Most recent ldl-c under control, results documented and reviewed
  • G8891 — Documentation of medical reason(s) for most recent ldl-c not under control (e.g., patients with palliative goals for whom treatment of hypertension with standard treatment goals is not clinically appropriate)
  • G8892 — Documentation of medical reason(s) for not performing ldl-c test (e.g. patients with palliative goals or for whom treatment of hypertension with standard treatment goals is not clinically appropriate)
  • G8893 — Most recent ldl-c not under control, results documented and reviewed
  • G8894 — Ldl-c not performed, reason not given
  • G8895 — Oral aspirin or other antithrombotic therapy prescribed
  • G8896 — Documentation of medical reason(s) for not prescribing oral aspirin or other antithrombotic therapy (e.g., patient documented to be low risk or patient with terminal illness or treatment of hypertension with standard treatment goals is not clinically appropriate, or for whom risk of aspirin or other antithrombotic therapy exceeds potential benefits such as for individuals whose blood pressure is poorly controlled)
  • G8897 — Oral aspirin or other antithrombotic therapy was not prescribed, reason not given
  • G8904 — I intend to report the hypertension (htn) measures group
  • G8905 — I intend to report the cardiovascular prevention measures group
  • G8930 — Assessment of depression severity at the initial evaluation
  • G8931 — Assessment of depression severity not documented, reason not given
  • G8932 — Suicide risk assessed at the initial evaluation
  • G8933 — Suicide risk not assessed at the initial evaluation, reason not given
  • G8943 — Ldl-c result not present or not within 12 months prior
  • G8949 — Documentation of patient reason(s) for patient not receiving counseling for diet and physical activity (e.g., patient is not willing to discuss diet or exercise interventions to help control blood pressure, or the patient said he/she refused to make these changes)
  • G8957 — Patient not receiving maintenance hemodialysis in an outpatient dialysis facility
  • G9193 — Clinician documented that patient with a diagnosis of major depression was not an eligible candidate for antidepressant medication treatment or patient did not have a diagnosis of major depression
  • G9194 — Patient with a diagnosis of major depression documented as being treated with antidepressant medication during the entire 180 day (6 month) continuation treatment phase
  • G9195 — Patient with a diagnosis of major depression not documented as being treated with antidepressant medication during the entire 180 day (6 months) continuation treatment phase
  • G9199 — Venous thromboembolism (vte) prophylaxis not administered the day of or the day after hospital admission for documented reasons (eg, patient is ambulatory, patient expired during inpatient stay, patient already on warfarin or another anticoagulant, other medical reason(s) or eg, patient left against medical advice, other patient reason(s))
  • G9200 — Venous thromboembolism (vte) prophylaxis was not administered the day of or the day after hospital admission, reason not given
  • G9201 — Venous thromboembolism (vte) prophylaxis administered the day of or the day after hospital admission
  • G9202 — Patients with a positive hepatitis c antibody test
  • G9214 — Cd4+ cell count or cd4+ cell percentage results documented
  • G9215 — Cd4+ cell count or percentage not documented as performed, reason not given
  • G9216 — Pcp prophylaxis was not prescribed at time of diagnosis of hiv, reason not given
  • G9218 — Pcp prophylaxis was not prescribed within 3 months oflow cd4+ cell count below 500 cells/mm3 or a cd4 percentage below 15%, reason not given
  • G9220 — Pneumocystis jiroveci pneumonia prophylaxis not prescribed within 3 months of low cd4+ cell count below 500 cells/mm3 or a cd4 percentage below 15% for medical reason (i.e., patient's cd4+ cell count above threshold within 3 months after cd4+ cell count below threshold, indicating that the patient's cd4+ levels are within an acceptable range and the patient does not require pcp prophylaxis)
  • G9221 — Pneumocystis jiroveci pneumonia prophlaxis prescribed
  • G9224 — Documentation of medical reason for not performing foot exam (e.g., patient with bilateral foot/leg amputation)
  • G9248 — Patient did not have a medical visit in the last 6 months
  • G9249 — Patient had a medical visit in the last 6 months
  • G9252 — Adenoma(s) or other neoplasm detected during screening colonoscopy
  • G9253 — Adenoma(s) or other neoplasm not detected during screening colonoscopy
  • G9271 — Ldl value < 100
  • G9272 — Ldl value >= 100
  • J0150 — Injection, adenosine for therapeutic use, 6 mg (not to be used to report any adenosine phosphate compounds, instead use a9270)
  • J0151 — Injection, adenosine for diagnostic use, 1 mg (not to be used to report any adenosine phosphate compounds, instead use a9270)
  • J0900 — Injection, testosterone enanthate and estradiol valerate, up to 1 cc
  • J1060 — Injection, testosterone cypionate and estradiol cypionate, up to 1 ml
  • J1070 — Injection, testosterone cypionate, up to 100 mg
  • J1080 — Injection, testosterone cypionate, 1 cc, 200 mg
  • J2271 — Injection, morphine sulfate, 100mg
  • J2275 — Injection, morphine sulfate (preservative-free sterile solution), per 10 mg
  • J3120 — Injection, testosterone enanthate, up to 100 mg
  • J3130 — Injection, testosterone enanthate, up to 200 mg
  • J3140 — Injection, testosterone suspension, up to 50 mg
  • J3150 — Injection, testosterone propionate, up to 100 mg
  • J7335 — Capsaicin 8% patch, per 10 square centimeters
  • J9265 — Injection, paclitaxel, 30 mg
  • L6025 — Transcarpal/metacarpal or partial hand disarticulation prosthesis, external power, self-suspended, inner socket with removable forearm section, electrodes and cables, two batteries, charger, myoelectric control of terminal device
  • L7260 — Electronic wrist rotator, otto bock or equal
  • L7261 — Electronic wrist rotator, for utah arm
  • M0064 — Brief office visit for the sole purpose of monitoring or changing drug prescriptions used in the treatment of mental psychoneurotic and personality disorders
  • Q9970 — Injection, ferric carboxymaltose, 1mg
  • Q9972 — Injection, epoetin beta, 1 microgram, (for esrd on dialysis)
  • Q9973 — Injection, epoetin beta, 1 microgram, (non-esrd use)
  • Q9974 — Injection, morphine sulfate, preservative-free for epidural or intrathecal use, 10 mg
  • S0144 — Injection, propofol, 10 mg
  • S3855 — Genetic testing for detection of mutations in the presenilin - 1 gene

Added effective February 5, 2015 (2)

  • G0296 — Counseling visit to discuss need for lung cancer screening using low dose ct scan (ldct) (service is for eligibility determination and shared decision making)
  • G0297 — Low dose ct scan (ldct) for lung cancer screening

Added effective April 1, 2015 (8)

  • C2623 — Catheter, transluminal angioplasty, drug-coated, non-laser
  • C9445 — Injection, c-1 esterase inhibitor (recombinant), ruconest, 10 units
  • C9448 — Netupitant 300 mg and palonosetron 0.5 mg, oral
  • C9449 — Injection, blinatumomab, 1 mcg
  • C9450 — Injection, fluocinolone acetonide intravitreal implant, 0.01 mg
  • C9451 — Injection, peramivir, 1 mg
  • C9452 — Injection, ceftolozane 50 mg and tazobactam 25 mg
  • Q9975 — Injection, factor viii fc fusion protein (recombinant), per iu

Deleted effective April 1, 2015 (1)

  • C9136 — Injection, factor viii, fc fusion protein, (recombinant), per i.u.

Added effective April 13, 2015 (1)

  • G0475 — Hiv antigen/antibody, combination assay, screening

Added effective July 1, 2015 (8)

  • C2613 — Lung biopsy plug with delivery system
  • C9453 — Injection, nivolumab, 1 mg
  • C9454 — Injection, pasireotide long acting, 1 mg
  • C9455 — Injection, siltuximab, 10 mg
  • Q5101 — Injection, filgrastim-sndz, biosimilar, (zarxio), 1 microgram
  • Q9976 — Injection, ferric pyrophosphate citrate solution, 0.1 mg of iron
  • Q9977 — Compounded drug, not otherwise classified
  • Q9978 — Netupitant 300 mg and palonosetron 0.5 mg

Deleted effective July 1, 2015 (3)

  • C9448 — Netupitant 300 mg and palonosetron 0.5 mg, oral
  • C9737 — Laparoscopy, surgical, esophageal sphincter augmentation with device (e.g., magnetic band)
  • S8262 — Mandibular orthopedic repositioning device, each

Added effective July 9, 2015 (1)

  • G0476 — Infectious agent detection by nucleic acid (dna or rna); human papillomavirus (hpv), high-risk types (e.g., 16, 18, 31, 33, 35, 39, 45, 51, 52, 56, 58, 59, 68) for cervical cancer screening, must be performed in addition to pap test

Added effective October 1, 2015 (4)

  • C9456 — Injection, isavuconazonium sulfate, 1 mg
  • C9457 — Injection, sulfur hexafluoride lipid microsphere, per ml
  • C9743 — Injection/implantation of bulking or spacer material (any type) with or without image guidance (not to be used if a more specific code applies)
  • Q9979 — Injection, alemtuzumab, 1 mg

Added effective November 2, 2015 (2)

  • G0299 — Direct skilled nursing services of a registered nurse (rn) in the home health or hospice setting, each 15 minutes
  • G0300 — Direct skilled nursing services of a licensed practical nurse (lpn) in the home health or hospice setting, each 15 minutes

Source: CMS HCPCS Level II alpha-numeric file (add and termination dates).

Source data

Source organization
CMS
Source release
HCPCS Level II October 2026 alpha-numeric file
Source file
october-2026-alpha-numeric-hcpcs-file.zip
File checksum (SHA-256)
c25240c63108756d4ba6c0ea785c517117d83bfed9526c51da8acf123de1feb6
Data read date
Data not available in the current MedCoder release record.
Effective date
CMS effective dates within 2015
Release type
Quarterly (January, April, July, October), with occasional mid-quarter additions
Methodology
Each code's add date and termination date are read from the alpha-numeric file. A deletion is dated the first day the code is no longer valid, the day after its termination date. Description revisions are not recorded as changes.

These changes are based on recorded release data. MedCoder does not generate coding changes with AI.

All releases in the Change Ledger